Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Autor: Carol Aghajanian, Lee-may Chen, Scott H. Kaufmann, Amit M. Oza, Geoffrey I. Shapiro, Rebecca Kristeleit, Sandra Goble, Iain A. McNeish, Diane Provencher, Ana Oaknin, Alexandra Leary, Lara Maloney, Elizabeth M. Swisher, Isabelle Ray-Coquard, Howard A. Burris, Stephen Welch, Kevin K. Lin, Tanya Kwan, Ronnie Shapira-Frommer, Anna V. Tinker, David M. O'Malley, Robert L. Coleman
Přispěvatelé: Cancer Research UK, Ovarian Cancer Action, National Institute for Health Research
Rok vydání: 2021
Předmět:
Oncology
Indoles
ANTITUMOR-ACTIVITY
MONOTHERAPY
Loss of Heterozygosity
DOUBLE-BLIND
chemistry.chemical_compound
Ovarian carcinoma
Aged
80 and over
Ovarian Neoplasms
Clinical Trials
Phase I as Topic
BRCA1 Protein
OLAPARIB
Obstetrics & Gynecology
Obstetrics and Gynecology
Structural variant
Genomics
Middle Aged
PARP inhibitor
SURVIVAL
RAD51C
Female
Safety
Life Sciences & Biomedicine
Adult
medicine.medical_specialty
CARCINOMA
Duration of response
Poly(ADP-ribose) Polymerase Inhibitors
Clinical Trials
Phase II as Topic
Internal medicine
GERMLINE
Post-hoc analysis
medicine
Humans
1112 Oncology and Carcinogenesis
Oncology & Carcinogenesis
Rucaparib
Aged
BRCA2 Protein
Science & Technology
MUTATIONS
business.industry
BRCA1
chemistry
PARP INHIBITOR RUCAPARIB
Recurrent Ovarian Cancer
1114 Paediatrics and Reproductive Medicine
Neoplasm Recurrence
Local
business
Recurrent Ovarian Carcinoma
Follow-Up Studies
Zdroj: Gynecologic Oncology. 163:490-497
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2021.08.030
Popis: Objective. To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. Methods. This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to
Databáze: OpenAIRE
Externí odkaz: